| |
 |
Norbrook Laboratories Limited Patents |
|
Assignee: Norbrook Laboratories Limited
Address: Newry, County Down, IE
No. of patents: 7
Patents:
| Patent Number |
Title Of Patent |
Date Issued |
| D659543 |
Container |
May 15, 2012 |
|
| 8216183 |
Heating device |
July 10, 2012 |
| A heating device (1) is described for a container (7) of a liquid pharmaceutical product having a viscosity of 50-500 cP at 4.degree. C. and contained within a glass container. The device (1) comprises a substantially rigid, thin-walled housing (2) defining an openable chamber for re |
| 7879899 |
Injectable veterinary composition for small animals |
February 1, 2011 |
| An injectable aqueous composition for veterinary use containing a non-steroidal anti-inflammatory compound in an amount of from about 0.25 to 30% (w/v) together with a physiologically acceptable oxygenated polymeric surfactant in an amount of from about 0.5 to 20% (w/v). |
| 6925963 |
Pet blanket |
August 9, 2005 |
| A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the |
| 6805076 |
Pet blanket |
October 19, 2004 |
| A pet blanket providing anti-flea properties is disclosed. The blanket is formed of an upper, permeable layer and a lower, impermeable layer, which together form a closeable pocket for receiving an insert that is impregnated with one or more anti-flea agents. As a pet reclines on the |
| 6310053 |
Long-acting oxytetracycline composition |
October 30, 2001 |
| An injectable composition is described having a higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis. The composition contains as active principle a tetracycline compound, either as the free base or a salt thereof |
| 6110905 |
Long-acting oxytetracycline composition |
August 29, 2000 |
| An injectable composition of higher residual effect with reduced detrimental effects such as pain at injection site, swelling, tissue irritancy or necrosis and containing as active principle a tetracycline compound, either as the free base or a salt thereof with a physiologically acc |
|
|
|
